- Home
- RNW vs IMCR Comparison
RNW vs IMCR Comparison
Compare RNW & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNW
- IMCR
- Stock Information
- Founded
- RNW 2011
- IMCR 2008
- Country
- RNW United Kingdom
- IMCR United Kingdom
- Employees
- RNW N/A
- IMCR N/A
- Industry
- RNW Electric Utilities: Central
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNW Utilities
- IMCR Health Care
- Exchange
- RNW Nasdaq
- IMCR Nasdaq
- Market Cap
- RNW 2.7B
- IMCR 1.8B
- IPO Year
- RNW N/A
- IMCR 2021
- Fundamental
- Price
- RNW $7.62
- IMCR $35.24
- Analyst Decision
- RNW Strong Buy
- IMCR Buy
- Analyst Count
- RNW 1
- IMCR 8
- Target Price
- RNW $7.50
- IMCR $57.00
- AVG Volume (30 Days)
- RNW 810.7K
- IMCR 281.5K
- Earning Date
- RNW 08-13-2025
- IMCR 11-05-2025
- Dividend Yield
- RNW N/A
- IMCR N/A
- EPS Growth
- RNW 1063.89
- IMCR N/A
- EPS
- RNW 0.28
- IMCR N/A
- Revenue
- RNW $1,320,468,726.00
- IMCR $356,145,000.00
- Revenue This Year
- RNW N/A
- IMCR $31.83
- Revenue Next Year
- RNW $16.12
- IMCR $8.50
- P/E Ratio
- RNW $27.26
- IMCR N/A
- Revenue Growth
- RNW 37.94
- IMCR 26.78
- 52 Week Low
- RNW $5.15
- IMCR $23.15
- 52 Week High
- RNW $7.89
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- RNW 49.50
- IMCR 56.75
- Support Level
- RNW $7.61
- IMCR $35.33
- Resistance Level
- RNW $7.84
- IMCR $37.16
- Average True Range (ATR)
- RNW 0.14
- IMCR 1.36
- MACD
- RNW -0.02
- IMCR 0.32
- Stochastic Oscillator
- RNW 50.46
- IMCR 53.39
About RNW ReNew Energy Global plc
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.